Related Experiment Videos
201Tl-labelled TlCl dosimetry revisited
1Brigham and Women's Hospital, Department of Radiology, Harvard Medical School, Boston, MA 02115.
Nuclear Medicine Communications
|February 1, 1993
Summary
Human dosimetry for 201Tl-labelled thallous chloride shows significant discrepancies. Recalculated kidney radiation dose aligns with previous reports, while gastrointestinal tract doses are higher.
Area of Science:
- Nuclear medicine
- Radiopharmacology
- Radiation dosimetry
Background:
- Literature review on 201Tl-labelled thallous chloride dosimetry reveals varied organ absorbed doses.
- A recent study reported significantly lower kidney dosimetry (0.0647 mGy/MBq) compared to established values (0.326 mGy/MBq).
Purpose of the Study:
- To re-evaluate human dosimetry for 201Tl-labelled thallous chloride.
- To resolve discrepancies in reported kidney dosimetry.
- To update absorbed doses for the gastrointestinal tract (GIT).
Main Methods:
- Literature review and analysis of existing human dosimetry data for 201Tl.
- Recalculation of kidney dosimetry using pharmacodynamic data from a recent study.
- Assessment of absorbed doses to the gastrointestinal tract (GIT).
Main Results:
- Recalculation yielded a kidney radiation dose of 0.514 mGy/MBq, consistent with earlier findings.
- Revised absorbed doses to the gastrointestinal tract (GIT) were found to be significantly higher than previously reported.
- Discrepancies in kidney dosimetry were resolved through recalculation.
Conclusions:
- The recalculated kidney dosimetry for 201Tl-labelled thallous chloride supports previously established values.
- Revised gastrointestinal tract (GIT) dosimetry indicates potentially higher radiation exposure.
- Accurate dosimetry is crucial for radiation safety in nuclear medicine procedures.